Table 1.
Characteristics of residential studies.
| Duration | Treatment | Dose (IU) | Regimen | Number | Female (%) | Age mean (SD) |
Vitamin D (nmol/L)# mean (SD) or median (IQR) |
Ca+ intake (mg/day) mean (SD) or median (IQR) |
|
|---|---|---|---|---|---|---|---|---|---|
| Chapuy | 3 years |
All | 3270 | 100 | 84 (6) | NA | 513 | ||
| D3 | 800 daily | CaD | 1634 | 84 (6) | 40 (28) | 511 (172) | |||
| P | P | 1636 | 84 (6) | 33 (23) | 514 (158) | ||||
| Decalyos II | 2 years | All | 583 | 100 | 85 (7) | 557.7 | |||
| D3 | 800 daily | CaD fixed CaD split |
393 | 85 (7) 85 (7) |
21 (13) 23 (17) |
565 (230) 551 (238) |
|||
| P | P | 190 | 86 (8) | 23 (17) | 556 (246) | ||||
| Flicker | 2 years | All | 625 | 95 | 83 | 25–90 | NA | ||
| D2 | 10000 weekly§ | CaD | 312 | 84 (8) | NA | NA | |||
| P | CaP | 313 | 83 (9) | NA | NA | ||||
| Lips-combined | Max. 3.5 years | All | 2578 | 74 | 80 (6) | NA | |||
| D3 | 400 daily | D | 1291 | 80 (6) | 27 [19–36] |
NA | |||
| P | P | 1287 | 80 (6) | 26 [19–37] |
NA | ||||
| Ooms | 2 years | All | 348 | 100 | |||||
| D3 | 400 daily | D | 177 | 80 (6) | 68 [48–90] |
876 [638–1101] |
|||
| P | P | 171 | 81 (6) | 63 [48–93] |
859 [644–1099] |
||||
| Meyer | 2 years | All | 1144 | 75 | 85 (7) | ||||
| D3 | 440 daily | D | 569 | 84 (7) | 47 (26) | 456 (196) | |||
| P | P | 575 | 85 (7) | 51 (33) | 446 (196) | ||||
| Heikinheimo residential | Range 2–5 years | All | 320 | 82 | NA | NA | NA | ||
| D2 | 150000–300000 yearly* | D | 142 | 79 | NA | NA | |||
| P | P | 178 | 79 | NA | NA | ||||
| Lyons | 3 years | All | 3440 | 76 | 84 (8) | NA | NA | ||
| D2 | 100000 4 monthly |
D | 1725 | 76 | 84 (8) | NA | NA | ||
| P | P | 1715 | 77 | 84 (8) | NA | NA |
*IM treatment.
§Changed to 1000 IU daily during the course of the study.
#Divide by 2.5 for ng/mL. IU: international units; D2: ergocalciferol; D3: cholecalciferol; D: vitamin D; CaD: calcium and vitamin D; Ca: calcium; P: placebo or control; NA: not available.